In this issue of Clinical Cancer Research, Reni and colleagues report the results from an
open-label, randomized, phase 2 trial investigating the effect of metformin in patients with metastatic pancreatic cancer (1) . Study patients were randomized to receive a chemotherapeutic regimen (i.e., cisplatin, epirubicin, capecitabine, gemcitabine [PEXG)]) with or without metformin at a dose of 2 gm daily. Based on a preplanned interim analysis performed after the first 60 patients were enrolled, metformin use was not associated with a survival benefit, and the trial was terminated early for futility. Overall Metformin is a biguanide used as an oral hypoglycemic agent in the treatment of type 2 diabetes mellitus. The mechanism of action by which metformin lowers blood glucose is not entirely understood, but it appears to involve decreasing hepatic glucose production and increasing insulin sensitivity. Metformin is inexpensive and well tolerated, thus making it a suitable candidate as a chemopreventive agent. It has been evaluated as a therapeutic agent in non-diabetic conditions such as polycystic ovary syndrome and nonalcoholic steatohepatitis (6, 7) . In vitro studies suggest that metformin may inhibit the growth of pancreatic cells through several mechanisms (Figure 1 ). One mechanism is related to its effects on lowering insulin and IGF1 levels. Metformin may also have direct inhibitory effects by activating the AMPK protein, a serine/threonine kinase activated in adenosine monophosphate rich states and hypoxia (8) . AMPK in turn phosphorylates and inactivates proteins in the mTOR pathway, a regulatory pathway that inhibits cell proliferation, polarity, and division (9) .
Consistent with these experimental data, metformin has been found in some observational studies to be associated with reductions in the incidence of and mortality from various cancers including pancreatic cancer (10, 11) . However, the validity of many of these studies has been questioned because time-related biases (e.g., immortal-time bias) could have led to the observed benefit (12) . Furthermore, two (13, 14) of the three studies that specifically examined the impact of metformin on pancreatic cancer survival failed to observe a survival benefit from metformin in pancreatic cancer patients, particularly among those with advanced disease. Therefore, observational data were inconclusive (15) provide much needed clarity on this issue. Despite the many differences in study design between the two trials (e.g., eligible cancer stage, chemotherapy regimen, blinding, use of placebo, interim analysis/early termination), their results are remarkably consistent. They both demonstrate that metformin at a dose typical for glycemic control is unlikely to impart a survival benefit in patients with metastatic pancreatic cancer.
There is no shortage of examples where compelling experimental evidence of a drug effect, either beneficial or harmful, fails to translate into a clinically important difference (e.g., statin as a chemopreventive agent for colorectal cancer). One possible reason is that the drug concentration in the target tissue necessary to observe an effect on the benchside might not be attainable with the drug doses typical for its usual clinical indication(s).
Another explanation for the lack of survival benefit might be that the anti-tumor effect of metformin is too modest to be clinically important in the setting of large tumor burden and aggressive tumor biology. Indeed, none of the previous observational studies demonstrated a survival benefit of metformin in patients with advanced stage pancreatic cancer (11, 13, 14) .
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In conclusion, the study by Reni and colleagues (1) contributes important data on a controversial issue. It corroborates the findings from another clinical trial. These clinical trial data can help guide the focus of future studies in this line of research. For example, they support the rationale for the ongoing exploration on the potential role of metformin as a form of maintenance therapy in patients with stabilized metastatic cancer (ClinicalTrials.gov: NCT02048384) or perhaps, metformin might be worth evaluation in the neoadjuvant setting. They also point to the need for clinical trials to determine whether metformin offers any survival advantage among patients with resectable pancreatic cancer.
